근거중심 한국형 우울증 약물학적 치료지침, 개정판(II) : 항우울제의 위약대비 효과, 항우울제간 효과차이 및 효과판정의 적정시점
Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II) : Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives The purpose of this study was to suggest recommendations of antidepressant efficacy compared with placebo, difference in efficacy of antidepressants, and appropriate time of efficacy judgment in antidepressant therapy. Methods Using recommendations from 12 international and domestic clinical practice guidelines for depression, drawing of recommendation drafts, and peer review, the executive committee developed the guideline. Results Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOI), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), norepinephrine and specific serotonergic antidepressants (NaSSAs), norepinephrine and dopamine reuptake inhibitors (NDRIs), and serotonin antagonist and reuptake inhibitors (SARIs) were strongly recommended as having antidepressant efficacy compared with placebo. Difference in efficacy of antidepressants was as follows. TCAs, MAOI, SSRI, SNRIs, and NaSSAs were strongly recommended, however, NDRIs, SARIs were weakly recommended. If there was no or minimal improvement with treatment, appropriate time of efficacy judgment in antidepressant therapy was estimated to be after two to four weeks. Conclusion We hope that the results of this study will be helpful in encouraging the optimal treatment by understanding antidepressant efficacy compared with placebo, difference in efficacy of antidepressants, and appropriate time of efficacy judgment in antidepressant therapy.
Abstract
Objectives The purpose of this study was to suggest recommendations of antidepressant efficacy compared with placebo, difference in efficacy of antidepressants, and appropriate time of efficacy judgment in antidepressant therapy. Methods Using recommendations from 12 international and domestic clinical practice guidelines for depression, drawing of recommendation drafts, and peer review, the executive committee developed the guideline. Results Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOI), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), norepinephrine and specific serotonergic antidepressants (NaSSAs), norepinephrine and dopamine reuptake inhibitors (NDRIs), and serotonin antagonist and reuptake inhibitors (SARIs) were strongly recommended as having antidepressant efficacy compared with placebo. Difference in efficacy of antidepressants was as follows. TCAs, MAOI, SSRI, SNRIs, and NaSSAs were strongly recommended, however, NDRIs, SARIs were weakly recommended. If there was no or minimal improvement with treatment, appropriate time of efficacy judgment in antidepressant therapy was estimated to be after two to four weeks. Conclusion We hope that the results of this study will be helpful in encouraging the optimal treatment by understanding antidepressant efficacy compared with placebo, difference in efficacy of antidepressants, and appropriate time of efficacy judgment in antidepressant therapy.
참고문헌 (67)
- 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
- Lopez AD, "Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data", The Lancet, 367, pp.1747~1757 (2006)
- Musselman DL, "Paroxetine for the prevention of depression induced by high-dose interferon alfa", N Engl J Med, 344, pp.961~966 (2001)
- Rudisch B, "Epidemiology of comorbid coronary artery disease and depression", Biological Psychiatry, 54, pp.227~240 (2003)
- Cleland JA, "Associations of depression and anxiety with gender, age, health-related quality of life and symptoms in primary care COPD patients", Family Practice, 24, pp.217~223 (2007)
- Robinson RG, "Poststroke depression: prevalence, diagnosis, treatment, and disease progression", Biological Psychiatry, 54, pp.376~387 (2003)
- Goldney RD, "Asthma symptoms associated with depression and lower quality of life: a population survey", Medical Journal of Australia, 178, pp.437~441 (2003)
- Chun TH, "The asthma", mental health nexus in a population-based sample of the United States, 2008, pp.134, 1176~1182
- Textbook of depressive disorder, "Korean society for depressive and bipolar disorders", pp.41~82 (2012), Sigmapress
- Jamison K, "Manic-depressive illness, creativity and leadership. Manic- Depressive Illness", 332~367 (1990)
- Nelson J, "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials", American Journal of Psychiatry, 166, pp.980~991 (2009)
- Arroll B, "Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis", The Annals of Family Medicine, 449~456 (2005)
- Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression, "Bech P", The British Journal of Psychiatry, 421~428 (2000)
- Freemantle N, "Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs Metaregression analysis", The British Journal of Psychiatry, 292~302 (2000)
- Cipriani A, "Fluoxetine versus other types of pharmacotherapy for depression", Cochrane Database, ~ (2005)
- Posternak MA, "Is there a delay in the antidepressant effect? A meta-analysis", The Journal of Clinical Psychiatry, 66, pp.148~158 (2005)
- Wade A, "The onset of effect for escitalopram and its relevance for the clinical management of depression", Current Medical Research and Opinion, 22, pp.2101~2110 (2006)
- Clinical Research Center for Depression, "Evidence-based Korean pharmacological treatment guideline for depression" (2008), ML Communication
- Clinical Research Center for Depression, "Evidence-based Korean nonpharmacological guideline for depression" (2009), ML Communication
- Clinical Research Center for Depression, "Evidence-based Korean pharmacological treatment guideline for depression, revised edition" (2012), ML Communication
- Huang X, "Evaluation of PICO as a knowledge representation for clinical questions", AMIA Annual Symposium Proceedings, pp.359~ (2006), American Medical Informatics Association
- Kim SY, "ADAPTE: Manual for guildeline adaptation version 1.0", National Clinical Research Coordination Center, ~ (2009)
- Steering Committee for Clinical Practice Guideline, "Korean Appraisal of Guidelines for Research & Evaluation II", Ministry of Health & Welfare and Korean Academy of Medical Science, ~ (2009)
- Network SIG, "SIGN 50: a guideline developer’s handbook: Scottish Intercollegiate Guidelines Network", ~ (2008)
- Fochtmann L, "Guideline watch: practice guideline for the treatment of patients with major depressive disorder", Am Psychiatric Assoc (2010)
- Pilling S, "Depression in adults, including those with a chronic physical health problem: Summary of NICE guidance", BMJ, pp.339~ (2009)
- Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines", J Psychopharmacol, 22, pp.343~396 (2008)
- Identification of Common Mental Disorders and Management of Depression in Primary Care, "New Zealand Group", Ministry of Health, ~ (2008)
- Professional Development & Quality Assurance prepared by a group of family physicians, "Guideline on Management of Depression in Primary Care Hong Kong", ~ (2005)
- Korean Medication Algorithm Project for Depressive Disorder, "Korean Medication Algorithm for Depressive Disorder 2008", Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology, ~ (2008)
- Depression. CRCf, "Evidence-based Korean pharmacological treatment guideline for depression" (2008), ML Communication
- Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care", World J Biol Psychiatry, 8, pp.67~104 (2007)
- Malhi GS, "Clinical practice recommendations for depression", Acta Psychiatr Scand Suppl, 4(Suppl 2), pp.8~26 (2009)
- Suehs B, "Texas Medication Algorithm Project procedural manual: major depressive disorder algorithms" (2008), Texas Department of State Health Services
- Lam RW, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults", J Affect Disord, 117, pp.26~43 (2009)
- Qaseem A, "Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians", Ann Intern Med, 149, pp.725~733 (2008)
- Klerman GL, "Clinical pharmacology of imipramine and related antidepressant compounds", Pharmacological Reviews, 17, pp.101~ (1965)
- Arroll B, "Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis", The Annals of Family Medicine, 3, pp.449~456 (2005)
- Bodkin JA, "Transdermal selegiline in major depression: a double- blind, placebo-controlled, parallel-group study in outpatients", Am J Psychiatry, 159, pp.1869~1875 (2002)
- Karasu T, "Practice guideline for the treatment of patients with major depressive disorder", Practice Guidelines for the Treatment of Psychiatric Disor, ~ (2000)
- Khan A, "Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database", Int J Neuropsychopharmacol, 4, pp.113~118 (2001)
- Bech P, "Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression", Br J Psychiatry, 176, pp.421~428 (2000)
- Perahia DG, "A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder", J Psychiatr Res, 42, pp.22~34 (2008)
- P. B, "Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression", Int J Neuropsychopharmacol, 4, pp.337~345 (2001)
- Pitts WM, "Bupropion in depression: a tri-center placebo-controlled study", J Clin Psychiatry, 44(5 Pt 2), pp.95~100 (1983)
- Fava M, "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL", Prim Care Companion J Clin Psychiatry, 7, pp.106~113 (2005)
- IM A, "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability", J Affect Disord, 58, pp.19~36 (2000)
- Anderson IM, "SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability", Depress Anxiety, 7(1), pp.11~17 (1998)
- Barbui C, "Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials", Br J Psychiatry, 178, pp.129~144 (2001)
- Guaiana G, "Amitriptyline versus other types of pharmacotherapy for depression", Cochrane Database Syst Rev, pp.CD004186~ (2003)
- Thase ME, "MAOIs in the contemporary treatment of depression", Neuropsychopharmacology, 12, pp.185~219 (1995)
- Quitkin F, "Monoamine oxidase inhibitors. A review of antidepressant effectiveness", Arch Gen Psychiatry, 36, pp.749~760 (1979)
- Henkel V, "Treatment of depression with atypical features: a meta-analytic approach", Psychiatry Res, 141, pp.89~101 (2006)
- Kennedy SH, "Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a metaanalysis", J Psychiatry Neurosci, 31, pp.122~131 (2006)
- Bauer M, "The effect of venlafaxine compared with other antidepressants and place bo in the treatment of major depression: a meta-analysis", Eur Arch Psychiatry Clin Neurosci, 259, pp.172~185 (2009)
- Geddes JR, "SSRIs versus other antidepressants for depressive disorder", pp.001851~ (2000), Cochrane Database Syst Rev
- Murdoch D, "Escitalopram: a review of its use in the management of major depressive disorder", Drugs, 65, pp.2379~2404 (2005)
- Gartlehner G, "Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians", Ann Intern Med, 149, pp.734~750 (2008)
- Thase ME, "Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder", J Clin Psychopharmacol, 27, pp.672~676 (2007)
- Papakostas GI, "Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches", Biol Psychiatry, 63, pp.699~704 (2008)
- Papakostas GI, "Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents", Biol Psychiatry, 62, pp.1217~1227 (2007)
- Papakostas GI, "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials", Journal of Psychiatric Research, 42, pp.134~140 (2008)
- Papakostas GI, "A metaanalysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder", J Clin Psychopharmacol, 26, pp.56~60 (2006)
- Posternak MA, M Z, "Is there a delay in the antidepressant effect? A meta-analysis", J Clin Psychiatry, 66, pp.148~158 (2005)
- Taylor MJ, "Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis", Arch Gen Psychiatry, 63, pp.1217~1223 (2006)
- Wade A, "The onset of effect for escitalopram and its relevance for the clinical management of depression", Curr Med Res Opin, 22, pp.2101~2110 (2006)
- Kim JM, "Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: The CRESCEND study", Journal of Affective Disorders, 129, pp.183~190 (2011)